23 January, 2026 in Investor Relations Nexalin Technology Receives Nasdaq Listing Status Notification
14 January, 2026 in Investor Relations Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
